195992-04-2

Upstream product

• 59382-59-1 2-methyl-3-nitro-benzoic acid methyl ester 
• 521074-26-0 methyl 3-nitro-2-{[(trifluoromethyl)sulfonyl]oxy}benzoate 
• 7486-35-3 tri-n-butyl(vinyl)tin 
• 22621-41-6 2-hydroxy-3-nitro-benzoic acid methyl ester 
• 98475-07-1 2-bromomethyl-3-nitro-benzoic acid methyl ester 
• 50-00-0 formaldehyd 

Downstream Products

• 110073-65-9 methyl 3-amino-2-ethenylbenzoate 
• 521074-27-1 3-nitro-2-vinylbenzoic acid 
• 521074-32-8 4-bromo-N-[8-ethyl-3-(hydroxymethyl)-7-quinolinyl]benzamide 
• 521074-33-9 4-bromo-N-[3-(chloromethyl)-8-ethyl-7-quinolinyl]benzamide hydrochloride 
• 521074-29-3 tert-butyl 3-amino-2-ethylphenylcarbamate 
• 521071-30-7 N-[8-ethyl-3-(1-pyrrolidinylmethyl)-7-quinolinyl]-4'-fluoro-[1,1'-biphenyl]-4-carboxamide 
• 521074-31-7 N-(3-amino-2-ethylphenyl)-4-bromobenzamide 

Relevant academic research and scientific papers

Melanin-concentrating hormone receptor 1 antagonists. Synthesis and structure-activity relationships of novel 3-(aminomethyl)quinolines

It was found that 3-(aminomethyl)quinoline derivatives showed high binding affinities for melanin-concentrating hormone receptor 1 (MCHR1) with reduced affinity for serotonin receptor 2c (5-HT2c) when the dihydronaphthalene nucleus of compound 1 (human MCHR1, IC50 = 1.9 nM; human 5-HT2c receptor, IC50 = 0.53 nM) was replaced by other bicyclic core scaffolds. Among the synthesized compounds, 8-methylquinoline derivative 5v especially showed high binding affinity (IC50 = 0.54 nM), potent in vitro antagonistic activity (IC50 = 2.8 nM) for MCHR1, and negligible affinity for 5-HT2c receptor (IC50 > 1000 nM). Oral administration of 5v significantly and dose-dependently suppressed nocturnal food intake in diet-induced obese rats and did not affect food intake in MCHR1-deficient mice. These results and rat pharmacokinetic study findings suggested that compound 5v is a highly potent, orally bioavailable, and centrally acting nonpeptide MCHR1 antagonist.

QUINOLINE COMPOUND

A compound, which has a melanin-concentrating hormone antagonistic action and useful as an agent for preventing or treating obesity, and which is represented by the formula: wherein Aris a cyclic group optionally having substituent(s) ;Xis a bond or a spacer having a main chain of 1 to 6 atoms;R1 and R2are the same or different and each is a hydrogen atom or a hydrocarbon group optionally having substituent(s), or R1 and R2 may form, together with the adjacent nitrogen atom, a nitrogen-containing heterocycle optionally having substituent(s);Yis a divalent hydrocarbon group optionally having substituent(s) (except CO);R3is a hydrogen atom or a hydrocarbon group optionally having substituent(s); andring A and ring Bmay further have substituents, and when ring B further has a substituent, the substituent may be linked to R1 to form a ring, or a salt thereof, or a prodrug thereof, is provided.

Palladium-Catalyzed Synthesis of Indoles by Reductive N-Heteroannulation of 2-Nitrostyrenes

A palladium-phosphine catalyzed reductive N-heteroannulation of 2-nitrostyrenes, in the presence of carbon monoxide, producing indoles has been developed. Indoles were obtained, in moderate to excellent yield, from substituted 2-nitrostyrenes having either electron-withdrawing (NO2 and CO2-Me) or electron-donating (Br, OH, Me, OMe, and OTf) substituents on the aromatic ring. Best results were obtained using palladium diacetate (6 mol percent) together with triphenylphosphine (24 mol percent) as the catalytic system, under 4 atm of carbon monoxide in acetonitrile at 70 °C. Other palladium(II) and palladium(0) complexes also catalyze the reaction.